georgie18
2週前
MBIO...258...🥳...WORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced that by decision dated November 8, 2024, the Nasdaq Hearings Panel granted the Company’s request for an extension to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the $1.00 bid price requirement through January 31, 2025 and the $2.5 million stockholders’ equity requirement through February 18, 2025. The Company is considering all available options that may enable it to timely evidence compliance with the continued listing criteria and maintain its listing on Nasdaq; however, there can be no assurance that the Company will be able to do so.
MBIO...266...🥳...https://www.globenewswire.com/news-release/2024/11/07/2976708/0/en/Mustang-Bio-Granted-Orphan-Drug-Designation-by-U-S-FDA-for-MB-108-HSV-1-oncolytic-virus-to-Treat-Malignant-Glioma.html
georgie18
Member Level
Re: georgie18 post# 206
Wednesday, October 30, 2024 12:45:35 PM
Post#
207
of 209
MBIO...33...Added here...Break/Hold .38 and she sees .50plus...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 662593
Friday, October 25, 2024 2:32:02 PM
Post#
662803
of 663273
MBIO...30s clearing here...🥳...Recent alert at .27 ran to .60 plus range...Break/Hold .37 is what I am looking for...then it should push .50 range...imo...we shall see...
georgie18
1月前
MBIO...61s clearing here...off my .27 Alert...🥳
georgie18
Member Level
Re: georgie18 post# 662291
Tuesday, October 22, 2024 4:39:28 PM
Post#
662292
of 662294
MBIO...43s clearing here...off my .27 Alert...🥳
georgie18
Member Level
Re: georgie18 post# 196
Tuesday, October 22, 2024 4:37:50 PM
Post#
197
of 197
MBIO...34s clearing ...getting some traction here...🥳off the .27 alert...
georgie18
Member Level
Re: georgie18 post# 662019
Tuesday, October 22, 2024 10:35:52 AM
Post#
662172
of 662290
MBIO...318...on the 50ma break...🥳
georgie18
Member Level
Re: None
Monday, October 21, 2024 2:43:46 PM
Post#
195
of 195
MBIO...27s clearing here...🥳...if it can hold the 50ma we can see the .31 Breakout...Psar flipped Bullish...
georgie18
1月前
MBIO...43s clearing here...off my .27 Alert...🥳
georgie18
Member Level
Re: georgie18 post# 196
Tuesday, October 22, 2024 4:37:50 PM
Post#
197
of 197
MBIO...34s clearing ...getting some traction here...🥳off the .27 alert...
georgie18
Member Level
Re: georgie18 post# 662019
Tuesday, October 22, 2024 10:35:52 AM
Post#
662172
of 662290
MBIO...318...on the 50ma break...🥳
georgie18
Member Level
Re: None
Monday, October 21, 2024 2:43:46 PM
Post#
195
of 195
MBIO...27s clearing here...🥳...if it can hold the 50ma we can see the .31 Breakout...Psar flipped Bullish...
Hercules1
5月前
Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months
All patients were heavily pretreated/refractory to BTK inhibitors, and only one patient has started new anti-WM treatment after MB-106
Outpatient administration was allowed and found to be feasible
Currently no FDA-approved CAR-T treatments for WM
Data presented at the European Hematology Association 2024 Hybrid Congress
WORCESTER, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced that updated data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T-cell therapy, show a favorable safety and efficacy profile in patients with Waldenstrom macroglobulinemia (“WM”), a rare form of blood cancer. MB-106 is being developed in a collaboration between Mustang and Fred Hutch Cancer Center (“Fred Hutch”) to treat patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHLs”) and chronic lymphocytic leukemia (“CLL”).